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Abstract
Background: The ATTRACT Trial previously reported that pharmacomechanical catheterdirected thrombolysis (PCDT) did not prevent the post-thrombotic syndrome (PTS) in patients
with acute proximal deep vein thrombosis (DVT). In the current analysis, we examine the effect
of PCDT in ATTRACT patients with iliofemoral DVT.
Methods: Within a large multicenter randomized trial, 391 patients with acute DVT involving
the iliac and/or common femoral veins were randomized to PCDT with anticoagulation versus
anticoagulation alone (No-PCDT) and were followed for 24 months to compare short-term and
long-term outcomes.
Results: Between 6 and 24 months, there was no difference in the occurrence of PTS (Villalta
scale >5 or ulcer: 49% PCDT versus 51% No-PCDT; risk ratio (RR)=0.95; 95% confidence
interval (CI), 0.78–1.15; p=0.59). PCDT led to reduced PTS severity as shown by: lower mean
Villalta and Venous Clinical Severity Scores [VCSS] (p<0.01 for comparisons at 6, 12, 18, and
24 months); and fewer patients with moderate-or-severe PTS (Villalta scale >10 or ulcer: 18%
versus 28%; RR 0.65; 95% CI 0.45–0.94, p=0.021) or severe PTS (Villalta scale >15 or ulcer:
8.7% versus 15%; RR 0.57; 95% CI 0.32-1.01, p=0.048; and VCSS >8: 6.6% versus 14%; RR
0.46; 95% CI 0.24-0.87, p=0.013). From baseline, PCDT led to greater reduction in leg pain and
swelling (p<0.01 for comparisons at 10 and 30 days) and greater improvement in venous diseasespecific QOL (VEINES-QOL unit difference 5.6 through 24 months, p=0.029), but no difference
in generic QOL (p > 0.2 for comparisons of SF-36 mental and physical component summary
scores through 24 months). In patients having PCDT versus No-PCDT, major bleeding within
10 days occurred in 1.5% versus 0.5% (p=0.32), and recurrent VTE over 24 months was
observed in 13% versus 9.2% (p=0.21).
Conclusions: In patients with acute iliofemoral DVT, PCDT did not influence the occurrence of
PTS or recurrent VTE. However, PCDT significantly reduced early leg symptoms and, over 24
months, reduced PTS severity scores, reduced the proportion of patients who developed
moderate-or-severe PTS, and resulted in greater improvement in venous disease-specific QOL.
Clinical Trial Registration: URL: www.clinicaltrials.gov Unique Identifier: NCT00790335
Key Words: deep vein thrombosis; iliofemoral; thrombolysis; post-thrombotic syndrome
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Clinical Perspective

What is new?
•

Outcomes are reported on a subgroup of 391 patients with acute iliofemoral DVT in
whom pharmacomechanical catheter-directed thrombolysis (PCDT) was evaluated within
a large multicenter randomized controlled trial (ATTRACT).

•

In patients with acute iliofemoral DVT, PCDT does not influence the occurrence of the
post-thrombotic syndrome (PTS) or recurrent venous thromboembolism through 24
months.

•

In patients with acute iliofemoral DVT, PCDT does appear to provide greater reduction
in acute leg pain and swelling through 30 days follow-up, as well as reduced PTS
severity, reduced moderate-or-severe PTS, and greater improvement in venous diseasespecific quality of life through 24 months.

What are the clinical implications?
•

The findings support early use of PCDT in patients with acute iliofemoral DVT who have
severe symptoms, low bleeding risk, and who attach greater importance to a reduction in
early and late symptoms than to the risks, costs, and inconvenience of PCDT.
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Introduction
Iliofemoral deep vein thrombosis (DVT), defined as DVT that involves the iliac and/or common
femoral vein (with or without involvement of additional veins), often causes functional
obstruction of venous outflow of the involved leg (1,2). These patients are phenotypically
distinct from patients with calf or femoral-popliteal DVT, based on more frequent recurrent
venous thromboembolic events, more frequent post-thrombotic syndrome (PTS), and more
severe PTS (1,3-7). Preliminary studies of catheter-directed thrombolysis and related methods
have suggested that these strategies may be most useful in patients with iliofemoral DVT
compared to those with less extensive proximal DVT, and that the occurrence and degree of
thrombus clearance may correlate with clinical outcome (8-13).
The biological plausibility that iliofemoral DVT should be recognized as a distinct entity
in the anatomic spectrum of acute DVT is rooted in the anatomy and physiology of lower
extremity venous return and the observation that venous recanalization occurs less often in
patients with iliofemoral versus more distal DVT who were treated with anticoagulation alone or
systemic thrombolysis (14,15). As the entire volume of venous blood return is directed through
the common femoral and iliac veins, obstruction of this channel results in marked postthrombotic venous hypertension (16) and severe post-thrombotic morbidity (3-7).
The main results of the Acute Venous Thrombosis: Thrombus Removal with Adjunctive
Catheter-Directed Thrombolysis (ATTRACT) Trial, the largest randomized trial evaluating
catheter based intervention for acute proximal DVT, were recently reported (17,18). This study
found no reduction of 2-year PTS frequency (the study’s primary outcome) or improvement in
health-related quality of life (QOL) in patients treated with pharmacomechanical catheterdirected thrombolysis (PCDT) compared with those treated with anticoagulation alone, although
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there was a reduction in the severity of PTS in the PCDT-treated group. Importantly, patients in
this study were stratified by the most proximal extent of their DVT (iliofemoral versus femoralpopliteal) prior to randomization, permitting a valid analysis of the outcomes of these two
distinct anatomic-clinical presentations. The purpose of this analysis is to report the benefits and
risks of PCDT in the patients in the ATTRACT Trial who presented with acute iliofemoral DVT.

Methods
Study Organization
The study design and the main study results for the overall ATTRACT cohort have been
previously described (17,18). In brief, this was a NIH-sponsored, Phase III, multicenter,
randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial
(www.attract.wustl.edu; NCT00790335). All patients provided written informed consent. The
study was approved by the Institutional Review Boards at all participating centers. The authors
and Steering Committee are solely responsible for the design and conduct of the study, all
analyses, and the writing of this article. The data and study materials will be made available to
other researchers in accordance with the NIH Public Access Policy, at www.clinicaltrials.gov or
by contacting the Corresponding Author.
Patient Population, Stratification, and Randomization
Patients presenting with DVT in the femoral or a more proximal vein with symptoms of 14 days
or less were enrolled from 56 centers in the United States (U.S.). Patients were stratified by
clinical center and by the most proximal extent of their DVT, that is, whether the DVT involved
the iliac and/or common femoral vein (“iliofemoral DVT”; this term applied whether or not more
caudal veins were also involved), or not (“femoral-popliteal DVT”) (1,2). After stratification,
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patients were randomized in a 1:1 ratio to receive either PCDT with anticoagulation (PCDT
Arm), or anticoagulation alone (No-PCDT Arm), and followed for 2 years. In this analysis, we
report exclusively on the 391 patients with iliofemoral DVT; the patients with femoral-popliteal
DVT are reported elsewhere.
Treatments
All patients were treated with initial and long-term anticoagulation consistent with published
guidelines (19,20), and were provided knee-high 30 – 40 mm Hg ankle gradient elastic
compression stockings (BSN Medical, Charlotte, NC) at their 10 day follow-up visit and every 6
months.
PCDT was performed as described elsewhere by board-certified physicians whose
credentials were approved by the trial leadership, using methods consistent with published
guidelines (21,22). Recombinant tissue plasminogen activator (rt-PA) (alteplase, Activase®,
Genentech, South San Francisco, CA) was infused into the thrombus using one of three methods:
a standard multi-sidehole catheter ("infusion-first"); the AngioJet Rheolytic Thrombectomy
System (Boston Scientific, Malborough, MA) (“power pulse-spray” or “rapid lysis” method); or
the Trellis Peripheral Infusion System (Covidien, Inc., Mansfield, MA [now Medtronic],
“isolated thrombolysis”). Rt-PA dosing limits were: 1) 0.01 mg/kg/hr, not to exceed 1.0 mg/hr;
2) no more than 30 hours infusion; 3) no more than 25 mg in any one procedure session; and 4)
no more than 35 mg total. After initial rt-PA delivery, physicians could use balloon maceration,
catheter aspiration, thrombectomy devices, and/or balloon angioplasty to clear residual
thrombus. Stent placement was encouraged for obstructive lesions in the iliac vein and/or
common femoral vein causing > 50% diameter narrowing, > 2 mmHg mean pressure gradient, or
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robust collateral filling on venography. Patients received heparin-based anticoagulation during
PCDT, as previously described (17,18).
Outcome Assessments
Patient outcomes were assessed at 10 and 30 days, and at 6, 12, 18, and 24 months following
randomization, by clinicians who were blinded to treatment allocation. The adjudicators of
safety and efficacy outcomes were also unaware of the treatment assignments.
PTS, defined as a Villalta score of > 5 or a venous ulcer in the leg with the index DVT
that occurred at any one or more assessments between the 6 month and 24 month follow-up visits
(inclusive), was the study’s primary efficacy outcome (23,24). The Villalta scale rates the
severity of five patient-reported symptoms (pain, cramps, heaviness, pruritus, paresthesia) and
six clinician-observed signs (edema, skin induration, hyperpigmentation, venous ectasia,
redness), with each item scored from 0-3. Points for symptoms and signs are summed into a total
score (range 0-33), and patients can be categorized as having no PTS (score 0-4), mild PTS
(score 5-9), moderate PTS (score 10-14) or severe PTS (score >15, or presence of ulcer).
Development of PTS was also attributed to patients if they underwent an unplanned
endovascular procedure to treat severe venous symptoms beyond 6 months after randomization,
unless there was a Villalta score < 5 in the previous 4 weeks.
The severity of PTS was evaluated at 6, 12, 18, and 24 months using the Villalta score
and the Venous Clinical Severity Score (VCSS) (25) as continuous measurements. In addition,
using the Villalta score, the presence of moderate or severe PTS (Villalta score ≥10, or an ulcer),
or severe PTS (Villalta score ≥15, or an ulcer) were assessed as secondary outcomes. Using the
VCSS (ranges from 0 to 27, with higher scores indicating more severe PTS), the presence of PTS
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(VCSS score ≥4) and severe PTS (VCSS score ≥8) were also assessed using previously
published criteria (26).
Generic health-related quality of life (QOL) was assessed with the SF-36 Health Status
Survey (27), and venous disease-specific QOL was assessed with the Venous Insufficiency
Epidemiological and Economic Study Quality of Life (VEINES-QOL) measure (28).
Leg pain and leg swelling were assessed at baseline, 10 days, and 30 days using a 7-point
Likert pain scale and by measuring calf circumference (29).
Patients receiving PCDT had the amount of thrombus removal quantified by independent
central readers using the proximal-vein components of the Marder score (30).
Safety outcomes included bleeding, recurrent venous thromboembolism, and death,
which were recorded throughout follow-up and summarized through 10 days and 24 months.
Clinically overt bleeding was classified as “major” if it was associated with a fall in the
hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement
of a critical site (e.g., intracranial, intraspinal) (31). Less severe clinically overt bleeding was
classified as “minor”.
Sample Size
Sample size for the entire ATTRACT study was 692 proximal DVT patients based on these
assumptions: 30% of control patients would develop PTS between 6 and 24 months; PCDT
would reduce PTS by at least 33%; 10% loss to follow-up; need to have 80% power to detect the
hypothesized treatment effect; acceptance of a two-side α error of 0.05. We did not estimate the
sample size for the iliofemoral DVT subgroup, pre-specify the proportion of patients expected to
have iliofemoral DVT, or require a minimum number of patients with iliofemoral DVT. A
sample size of 391, corresponding to the number of patients in the current analysis, provides
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approximately 80% power to detect (i) a 41% PTS reduction assuming a control proportion of
30%, and (ii) an effect size (i.e. mean difference divided by the SD) of at least 0.28, assuming a
two-sided α error of 0.05 with each type of analysis.
Statistical Analysis
Two types of analyses were performed: a modified intention-to-treat analysis (primary analysis)
that included all randomized patients except those who did not have DVT at enrollment; and a
per-protocol analysis (secondary analyses) that excluded patients who, within 7 days postrandomization, were randomized to PCDT but did not receive it, or who were randomized to
control but had skin puncture for PCDT thrombolysis or any thrombolytic therapy.
Cumulative proportions were compared using the Cochran-Mantel-Haenszel test adjusted
for clinical center. Treatment effects are summarized using stratum-adjusted risk ratios (RR)
with their corresponding 95% confidence intervals (CI).
The mean Villalta,VCSS, and QOL assessments at each visit were estimated using piecewise linear regression growth curve models adjusting for clinical center and pre-specified
baseline covariates (age, sex, body-mass index, race). Changes from baseline to 10 days and
from baseline to 30 days for leg pain scores and calf circumferences in the index leg were
compared using multiple linear regression, adjusted for clinical center. A supportive analysis
modeled the values at 10 days and 30 days with the baseline value as a covariate. For the binary
outcomes, interaction tests for subgroups were conducted using a logistic model with treatment,
subgroup, and an interaction term as factors, with interaction p-values calculated using Wald
joint tests. The risk ratios and 99% confidence intervals derived from the models were used to
create the forest plots.
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The analyses in this report are considered exploratory because, although they were prespecified, they are confined to a subgroup of the main trial.

Results
Baseline Characteristics of Participants
Of the 692 patients in ATTRACT, 391 (57%) had iliofemoral DVT of whom 196 were
randomized to PCDT and 195 were randomized to No-PCDT (Figure 1). Median age was 52
years, 53% were male, the index DVT was in the left leg in 64%, and symptoms were present for
a median of 6 days (Table 1). Baseline characteristics were well balanced between the two
treatment groups (Table 1)
Protocol and Treatment Adherence
Within 7 days after randomization, 4 patients assigned to No-PCDT had PCDT, and 6 patients
assigned to PCDT did not have the procedure (Figure 1). These patients were excluded from the
per-protocol analysis. PCDT was performed at a median one day post-randomization. Initial
anticoagulant therapy, which was usually low molecular weight heparin or unfractionated
heparin, was similar in the PCDT and No-PCDT patients (Table 2). The initial rt-PA delivery
method in PCDT Arm patients was the "infusion first" method in 52% (median total rt-PA dose
of 21 mg), the AngioJet method in 24% (median total rt-PA dose of 21 mg), and the Trellis
method in 19% (median total rt-PA dose of 20 mg) (PCDT not performed in 5%; Table 2). After
initial rt-PA delivery, additional endovascular methods were used in 91% of patients, as
summarized in Table 2. Mean thrombus removal as assessed by pre and post PCDT venography
was 86% (mean pre-procedure and post-procedure Marder scores 12.0 and 3.0, respectively,
change -9.1; 95% CI, -8.2 to -10.0; p <0.001). The mean duration of anticoagulation before first
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permanent cessation during follow-up, use of antiplatelet therapy, and use of compression
stockings were similar in the PCDT and No-PCDT patients (Table 2).
Development of Post-Thrombotic Syndrome
In the intention-to-treat analysis using the study’s primary outcome measure (Villalta scale), PTS
developed in 96 of 196 (49%) PCDT Arm patients and in 100 of 195 (51%) No-PCDT Arm
patients (RR=0.95; 95% CI, 0.78-1.15; p=0.59) during 24 months follow-up (Table 3). In the
per-protocol analysis and in all subgroups evaluated, the findings were similar (Figure 2,
Supplemental Table 1). Using the VCSS scale, PTS developed in 30% of PCDT Arm patients
and in 40% of No-PCDT Arm patients (RR=0.75; 95% CI, 0.57-0.98; p=0.034) (Table 3). In the
per-protocol analysis, these findings were similar (29% PCDT versus 41% No-PCDT, RR=0.71,
95% CI, 0.54-0.94, p=0.015) (Supplemental Table 1).
Severity of Post-Thrombotic Syndrome
At 6, 12, 18, and 24 months, mean Villalta and VCSS scores were significantly lower in the
PCDT Arm compared with the No-PCDT Arm (p< 0.01 at all time-points, both analysis sets)
(Table 4, Figure 3) (32).
Moderate-or-severe PTS, as assessed by a Villalta scale score ≥10 or ulceration,
developed in 36 (18%) patients assigned to PCDT and in 55 (28%) patients assigned to NoPCDT (RR=0.65; 95% CI, 0.45 to 0.94; p=0.021) (Table 3). The findings were similar in a perprotocol analysis (RR=0.63, p=0.013) (Supplemental Table 1). For this outcome, patients’ sex,
race, symptom duration (0-1 versus 1-2 weeks), side of DVT, and baseline symptom severity did
not influence the effect of PCDT. However, patients < 65 versus ≥ 65 years old (pinteraction=0.04) and those with versus without a major reversible DVT risk factor at diagnosis
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(p-interaction=0.05) appeared less likely to develop moderate-or-severe PTS with use of PCDT
(Figure 4).
Severe PTS, as assessed by a Villalta score ≥15 or ulceration, developed in 17 (8.7%)
patients assigned to PCDT and in 30 (15%) patients assigned to No-PCDT (RR=0.57; 95% CI,
0.32 to 1.01; p=0.048) (Table 3). Severe PTS, as assessed by a VCSS score > 8, developed in 13
(6.6%) patients assigned to PCDT and 28 (14%) patients assigned to No-PCDT (RR=0.46; 95%
CI, 0.24 to 0.87; p=0.013) (Table 3). These findings were similar in per-protocol analyses
(Supplemental Table 1). Ulceration developed in 9 (4.6%) patients assigned to PCDT and in 12
(6.2%) patients assigned to No-PCDT (RR=0.75; 95% CI, 0.32 to 1.73, p=0.49).
Change in Presenting Symptoms and Health-Related Quality of Life
Mean change in leg pain from baseline for PCDT versus No PCDT was -1.76 versus -1.25 Likert
points at 10 days (p=0.009), and -2.36 versus -1.80 Likert points at 30 days (p=0.008) (Table 4).
Mean change in calf circumference from baseline for PCDT versus No PCDT was -0.79 cm
versus +0.22 cm at 10 days (p=0.002) and -1.37 cm versus -0.10 cm at 30 days (p<0.001). The
findings for these outcomes were similar in the per-protocol analyses (Supplemental Table 2).
Mean change in venous disease-specific quality of life from baseline to 24 months was
28.6 versus 23.0 VEINES-QOL scale units in the PCDT versus No-PCDT Arms (between-group
difference 5.6 units, p=0.029). In the per-protocol analysis, this between-group difference was
5.3 units (p=0.04).
Mean change in the symptoms component of venous disease-specific quality of life from
baseline to 24 months was 21.5 versus 16.2 VEINES-Sym scale units in the PCDT versus NoPCDT Arms (between-group difference 5.2 points, p=0.043). In the per-protocol analysis, this
between-group difference was 5.1 units, p=0.012).
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Mean change in generic quality of life (physical and mental component summary scores
of SF-36 measure) from baseline to 24 months did not differ for the PCDT versus No-PCDT
patients in either the intention-to-treat or per-protocol analyses (p>0.25 for all analyses, Table 4,
Supplemental Table 2).
Safety Outcomes
Within 10 days, in PCDT versus No-PCDT patients, major bleeding occurred in three patients
(1.5%) versus one patient (0.5%) (p=0.32), and any bleeding occurred in seven (3.6%) versus
four (2.1%) patients (p=0.36) (Table 3). There were no fatal or intracranial bleeds. Recurrent
venous thromboembolism within 24 months occurred in 26 (13.3%) PCDT versus 18 (9.2%) NoPCDT patients (p=0.21) (none were fatal). Of the six deaths in each group, none occurred within
10 days post-randomization (Table 3). Per-protocol analyses of the safety outcomes were
similar (Supplemental Table 1).

Discussion
Contemporary clinical practice guidelines (including a Scientific Statement from the American
Heart Association) recommend that studies of DVT therapy report outcomes separately for
patients with iliofemoral versus less extensive DVT (1,2). These and other guidelines (19,20,22)
also identify thrombus extent as a key factor to consider when deciding which patients should
receive endovascular thrombus removal, which accounts for why some randomized trials have
evaluated endovascular DVT therapies exclusively in patients with iliofemoral DVT (33-35).
Consequently, this report focuses on findings in the iliofemoral DVT subgroup of the ATTRACT
study.
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Several studies have described favorable outcomes for aggressive thrombus removal
therapies in comparison to anticoagulation alone in iliofemoral DVT, but each had major
methodological limitations that undermine confidence in their findings. A small randomized
trial evaluating surgical venous thrombectomy for acute iliofemoral DVT versus anticoagulation
alone reported improved long term iliofemoral patency and reduced post-thrombotic morbidity in
the surgically-treated patients (36). A post-hoc analysis of data from a prospective multicenter
registry found that 68 CDT-treated patients had significantly fewer PTS symptoms, better
physical functioning, less stigmata of chronic venous insufficiency, and less health distress
(p<0.05 for all outcomes) at a mean follow-up of 16 months compared with 30 retrospectively
“matched” patients who were treated with anticoagulation alone (9). A prospective nonrandomized study (n=51) found better 6-month and 5-year venous patency and freedom from
venous symptoms in patients who received CDT versus anticoagulation alone (37). Finally, a
single-center randomized trial comparing streptokinase CDT versus anticoagulation alone
observed a higher rate of normal venous function and less valvular reflux in CDT recipients (38).
However, these studies were limited by potential selection bias and baseline differences between
treatment groups due to their non-randomized design (9,37), small sample size (9,36-38),
performance in a single center (37,38), and lack of rigorous PTS assessment with validated tools
(38).
A recent multicenter randomized trial that evaluated CDT for proximal DVT above midthigh level (the CAVENT Trial) found that CDT reduced PTS, which significantly correlated
with patency of the ipsilateral iliofemoral venous segment (11,13). Since CAVENT did not
report outcomes separately for iliofemoral DVT and femoral-popliteal DVT patients, we are
unable to combine data from the iliofemoral subgroups of the two trials. Although in the total
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study population, CAVENT reported that CDT reduced any PTS, CDT did not improve longterm QOL and was associated with major and non-major bleeding complications. Consequently,
we suggest that the findings of ATTRACT and CAVENT collective argue against routine firstline thrombolysis for proximal DVT, but that patients with iliofemoral DVT or more severe
presentations may derive benefit and deserve further examination.
This exploratory analysis of the iliofemoral DVT subgroup in the ATTRACT Trial did
not find an effect of PCDT upon the development of “any PTS” over 2 years using the prespecified primary trial outcome (Villalta score threshold of 5), and did not find an effect upon
bleeding. These findings were similar in the per-protocol analysis, and they are consistent with
PCDT treatment effects for “any PTS” in the iliofemoral and femoral-popliteal subgroups that
did not differ significantly (p-interaction=0.85) (18). Although PCDT reduced the occurrence of
PTS in a pre-specified secondary assessment using the VCSS, we chose the Villalta scale as the
trial’s primary outcome measure based upon a more extensive body of literature and
international societal recommendations supporting its use to detect incident PTS, including more
rigorous assessment of the Villalta threshold score than the VCSS threshold score (23-26).
Additional studies to compare the performance characteristics of these two PTS scales, using the
ATTRACT and other datasets, would be worthwhile.
The data from this analysis collectively suggest that PCDT improves short-term recovery
from DVT and reduces long-term progression of PTS severity in patients with iliofemoral DVT.
Evidence favoring PCDT includes: 1) greater reduction in leg pain and swelling through 30 days
(p<0.01); 2) reduced PTS severity (p<0.01 for Villalta and VCSS comparisons) at 6, 12, 18, and
24 months; 3) reduced occurrence of moderate-or-severe PTS (p=0.021 for comparison of
proportion with Villalta > 10) and severe PTS (p<0.05 for comparisons of proportions with
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Villalta > 15 and VCSS > 8) through 24 months; and 4) greater improvement in venous diseasespecific QOL from baseline to 24 months (5.6 points on VEINES-QOL scale, p=0.029). These
findings were consistent in the per-protocol analyses.
However, the findings of this analysis should not be considered conclusive evidence that
PCDT reduces the occurrence of moderate-or-severe PTS in patients with iliofemoral DVT.
Moderate-or-severe PTS was one of a number of secondary outcomes. Although assessors were
blinded to treatment arm, healthcare providers and patients were not blinded. Hence, further
studies are recommended to determine whether PCDT truly reduces moderate-or-severe PTS in
patients with iliofemoral DVT.
In this analysis, there was a suggestion that PCDT exerted a more positive effect upon the
moderate-or-severe PTS outcome in iliofemoral DVT patients who were < 65 years of age versus
those > 65 years old (p-interaction = 0.04), and upon patients whose DVT was provoked by a
major reversible risk factor (p-interaction = 0.05). However, as these two results are in
subgroups within the iliofemoral subgroup, and as they are among many outcomes that were
evaluated in the study, and as the tests of interaction were not strongly positive, these two
findings may have occurred by chance (39,40).
Our analysis has several limitations. First, there was substantial loss to follow-up that
was unbalanced between the treatment groups (more missed PTS assessments in the No-PCDT
Arm), which influenced the study’s estimates of treatment effects (18). As only 57% of
ATTRACT Trial patients had iliofemoral DVT, power to detect differences in outcomes with
PCDT versus No-PCDT in the iliofemoral DVT subgroup is substantially less than in the overall
trial. Furthermore, in the absence of a statistically significant test of interaction to support a
difference in the PCDT treatment effect upon moderate-or-severe PTS between the iliofemoral
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and femoral-popliteal subgroups, the treatment effect estimate from the overall trial may be the
most reliable estimate of the treatment effect in each of these two subgroups (39,40). This is also
true for the assessment of bleeding, which was statistically higher with use of PCDT in the
overall ATTRACT Trial. On the other hand, tests of interaction to detect differences in
treatment effects between subgroups have low power in a medium-sized study such as
ATTRACT. Strengths of this analysis include that it was pre-specified; that the presence of
iliofemoral DVT was a stratification variable that was identified prior to randomization; and that
the reduction in PTS severity with PCDT was a consistent finding across multiple venous
outcome measures. We excluded patients with either asymptomatic DVT or DVT causing acute
circulatory compromise since they could not be ethically randomized to one or the other
treatment strategy, and we acknowledge that a) the enrolled patients had varying baseline
symptom severity (and perhaps PTS risk); b) patients with recurrent ipsilateral DVT within the
last 2 years (who are expected to have a high risk of PTS) were excluded; and c) site
investigators could have chosen to bypass the study for selected patients at either end of the
severity spectrum. However, throughout the study we provided detailed education to study
centers that explicitly addressed this issue and strongly encouraged the enrollment of all willing
iliofemoral DVT patients who met the study eligibility criteria. This analysis is also the largest
report of randomized trial outcomes specifically in patients with iliofemoral DVT.
In conclusion, the findings of this exploratory analysis strongly suggest that PCDT
reduces acute leg pain and swelling, reduces PTS severity, and improves venous QOL in patients
with acute iliofemoral DVT. These findings support early use of PCDT in patients with acute
iliofemoral DVT who have severe symptoms, low bleeding risk, and who attach greater
importance to a reduction in early and late symptoms than to the risks, cost, and inconvenience
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of PCDT. A decision to use PCDT should factor in this study’s limitations (including the lack of
patient blinding) and should be made only after a careful review of the bleeding risk in that
individual patient. Further prospective study of PCDT and other endovascular therapies should
be targeted to the subset of patients with iliofemoral DVT.
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Table 1. Baseline Characteristics by Treatment Group
PCDT
n = 196

Baseline Characteristic

No PCDT
n = 195

Total
N = 391

Age, years: median (IQR)

51 (39, 62)

52 (42, 61)

52 (39, 62)

Male: n (%)

107 (55)

101 (52)

208 (53)

Race: n (%)
White

158 (81)

148 (76)

306 (78)

Black/African-American

33

(17)

35

(18)

68

(17)

Other

5

(3)

12

(6)

17

(4)

Body mass index, kg/m2: median (IQR)

31 (28, 37)

31 (26, 36)

31 (27, 37)

Symptom severity (Villalta*) class: n (%)†
None or minimal (score 0-4)

24

(12)

31

(16)

55

Mild (score 5-9)

65

(33)

65

(33)

130 (33)

Moderate (score 10-14)

60

(31)

56

(29)

116 (30)

Severe (score ≥ 15)

47

(24)

42

(22)

89

(14)

(23)

Leg with index DVT, Left: n (%)

124 (63)

125 (64)

249 (64)

Previous DVT or PE: n (%)

48

(24)

45

(23)

93

(24)

Previous ipsilateral DVT: n (%)

3

(2)

10

(5)

13

(3)

DVT risk factors: n (%)‡
Major surgery

19

(10)

21

(11)

40

(10)

Hospitalization

17

(9)

29

(15)

46

(12)

Plaster cast immobilization

7

(4)

3

(2)

10

(3)

Childbirth

3

(2)

5

(3)

8

(2)

Outpatient: n (%)
Days from start of DVT symptoms to rand: median
(IQR)
eGFR, mL/min: median (IQR)

156 (80)

156 (80)

312

(80)

6 (3, 9)

6 (3, 9)

6

84 (67, 103)

88 (72, 104)

86

(70, 103)
(20)

(3, 9)

Leg pain severity: n (%)
0-2

34

(17)

43

(22)

77

3-4

60

(31)

59

(30)

119 (30)

5-7

99

(51)

91

(47)

190 (49)

3

(2)

2

(1)

5

(1)

3

(2, 4)

3

(2, 5)

Unknown
Between-leg circumference difference§, cm:
median (IQR)

3 (2, 5)

24

PCDT
n = 196

Baseline Characteristic

No PCDT
n = 195

Total
N = 391

180

(92)

184

(94)

364

(93)

LMWH

101

(56)

110

(60)

211

(58)

UFH

61

(34)

60

(33)

121

(33)

Rivaroxaban

7

(4)

7

(4)

14

(4)

Warfarin

89

(49)

98

(53)

187

(51)

Pre-randomization ACǁ therapy: n (%)‡

Other
11
(6)
7
(4)
18
(5)
* Villalta Scale: 5 patient-reported signs (cramps, itching, pins & needles, leg heaviness, pain) and 6
blinded clinician-reported symptoms (pretibial edema, skin induration, hyperpigmentation, venous
ectasia, redness, pain during calf compression) scored on a 4-point scale (0=none/minimal, 1=mild,
2=moderate, 3=severe) and summed into a total score, or the presence of an ulcer (score=15), for the
leg with index DVT
†
One patient in the No PCDT was not assessed
‡
Subjects may fit into more than one category
§ Leg circumference with index DVT minus Leg circumference of the other leg
ǁ
Anticoagulant (AC) therapy that was given after DVT diagnosis and before randomization
IQR, inter-quartile range; DVT, deep vein thrombosis; PE, pulmonary embolism; rand, randomization;
eGFR, estimated glomerular filtration rate; LMWH, low molecular weight heparin; UFH,
unfractionated heparin
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Table 2. Study Treatments Post Randomization
Treatment over Time

PCDT
n = 196

No PCDT
n = 195

Initial AC* therapy: n (%)†

n = 194

n = 193

UFH

73

(38)

42

(22)

LMWH

99

(51)

132

(68)

29

(15)

28

(15)

Other
†

At 30 days: n (%)

n = 183

n = 173

Any AC Therapy

177

(97)

167

(97)

Antiplatelet Therapy

30

(16)

26

(15)

Compression stockings used ≥ 3 days per week

135

(74)

136

(79)

†

At 6 months: n (%)

n = 169

n = 150

Any AC Therapy

136

(80)

126

(84)

Antiplatelet Therapy

34

(20)

23

(15)

Compression stockings used ≥ 3 days per week

111

(66)

108

(72)

†

At 24 months: n (%)

n = 141

n = 131

Any AC Therapy

66

(47)

68

(52)

Antiplatelet Therapy

44

(31)

39

(30)

Compression stockings used ≥ 3 days per week

77

(55)

74

(56)

Never started

2

(1)

2

(1)

Not stopped during study period

106

(54)

108

(55)

Stopped during study period:

88

(45)

85

(44)

Duration of AC therapy: n (%)

Days to stopping: median (IQR)

213 (182, 367)

PCDT Procedure Details (PCDT Arm only)
Initial rt-PA delivery method:
102

Infusion-First: n (%)
rt-PA total dose, mg: median (IQR)

21

rt-PA duration, hours: % below 4h, mean (SD)

(52)
(18, 26)

0%,23 (7.2)

‡

46

AngioJet: n (%)

(24)

rt-PA total dose, mg: median (IQR)

21

rt-PA duration, hours: % below 4h, mean (SD)‡

46%, 20 (5.5)
38

Trellis: n (%)
rt-PA total dose, mg: median (IQR)

20

rt-PA duration, hours: % below 4h, mean (SD)

(15, 28)
(19)
(12, 30)

58%, 20(4.6)

‡

10

Other§: n (%)

26

(5)

270 (182, 395)

PCDT
n = 196

Treatment over Time

No PCDT
n = 195

Additional endovascular methods used: n (%)
None

18

(9)

178

(91)

Balloon venoplasty

128

(72)

Balloon maceration

105

(59)

Rheolytic thrombectomy (AngioJet)

104

(58)

Stent placement

70

(39)

Large-bore catheter aspiration

44

(25)

Isolated thrombolysis (Trellis)

11

(6)

192

(98)

Ipsilateral Popliteal Vein

172

(90)

Ipsilateral Tibial Vein

12

(6)

Ipsilateral Common Femoral Vein

5

(3)

1 or more
†

Type of additional method: n (%)

†

Veins that were accessed: n (%)

Internal Jugular Vein
12
(6)
Other Vein
17
(9)
Marder scores: median (IQR)
Pre-lysis (n=180)
11 (8, 16)
Post-lysis (n=178)
2 (0, 4)
Pre-post Decrease (n=176)
9 (4, 13)
*
Anticoagulation (AC) therapy given post randomization
†
Subjects may fit into more than one category
‡
Distributions are bimodal with spikes below 4 hours (means and SDs are for post 4-hour data)
§
6 PCDT procedures where there was no acute thrombus on venogram and 4 not attempted
IQR, Inter-quartile range; rt-PA, recombinant tissue plasminogen activator; SD, standard deviation
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Table 3. Binary Study Outcomes by Treatment Group (Intention-to-Treat Analysis)

Outcome

PCDT
n = 196
Events

No PCDT
n = 195
Events (%)

(%)

Risk Ratio

P Value

Estimate 95% CI

PTS*:
Ulcer (any assessment)
9
(4.6%)
12
(6.2%)
Villalta ≥ 5 (without ulcer)
86
(44%)
88
(45%)
Late endovascular procedure only
1
(0.5%)
0
(0%)
Total
96
(49%)
100
(51%)
0.95*
0.78, 1.15
0.59
PTS: VCSS ≥ 4*
59
(30%)
78
(40%)
0.75*
0.57, 0.98
0.034
PTS incidence proportion: †
At 6 months
50/169
(30%)
68/149 (46%)
0.65
0.48, 0.87
At 12 months
58/155
(37%)
49/137 (36%)
1.05
0.77, 1.42
At 18 months
46/139
(33%)
47/123 (38%)
0.87
0.63, 1.20
At 24 months
48/145
(33%)
52/133 (39%)
0.85
0.62, 1.16
‡
Moderate-severe PTS (Villalta ≥ 10)
36
(18%)
55
(28%)
0.65*
0.45, 0.94
0.021
Moderate-severe PTS incidence
proportion: §
At 6 months
19/169
(11%)
29/149 (19%)
0.58
0.34, 0.99
At 12 months
18/155
(12%)
24/137 (18%)
0.66
0.38, 1.17
At 18 months
16/139
(12%)
23/123 (19%)
0.62
0.34, 1.11
At 24 months
17/145
(12%)
25/133 (19%)
0.62
0.35, 1.10
Severe PTS: Villalta ≥ 15 ǁ
17
(8.7%)
30
(15%)
0.57*
0.32, 1.01
0.048
ǁ
Severe PTS: VCSS ≥ 8
13
(6.6%)
28
(14%)
0.46*
0.24, 0.87
0.013
Major non-PTS treatment failure
4
(2.0%)
5
(2.6%)
0.80
0.22, 2.92
0.73
Any treatment failure **
97
(49%)
103
(53%)
0.93*
0.77, 1.13
0.47
Major bleeding in first 10 days
3
(1.5%)
1
(0.5%)
2.98
0.31, 28.4
0.32
Any bleeding in first 10 days
7
(3.6%)
4
(2.1%)
1.74
0.52, 5.85
0.36
VTE:
First 30 days
11
(5.8%)
6
(3.1%)
1.82
0.69, 4.83
0.22
Total over 24 months
26
(13%)
18
(9.2%)
1.44
0.81, 2.53
0.21
Death
6
(3.1%)
6
(3.1%)
0.99
0.33, 3.03
0.99
* Cochran-Mantel-Haenszel (CMH) test adjusted for center, cumulative proportion of patients who developed PTS at any
time between 6-24 months, inclusive. Villalta scores (0-33 range); VCSS scores (0-27 range), higher is worse for both.
†
At each visit, the proportion of patients with any PTS according to the Villalta scale among those who had an assessment
performed (denominator)
‡
Cumulative proportion with moderate or severe PTS (pre-specified analysis)
§
At each visit, the proportion of patients with moderate or severe PTS according to the Villalta scale among those who had
an assessment performed (denominator)
ǁ
Cumulative proportion with severe PTS ** Composite of PTS or major non-PTS treatment failure.
PTS, post-thrombotic syndrome; CI, confidence interval; VTE, venous thromboembolism
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Table 4. Continuous Study Outcomes by Treatment Group (Intention-to-Treat Analysis)
Outcome

PCDT
n = 196
n
mean (SE)

No PCDT
n = 195
n
mean (SE)

PCDT – No PCDT
Difference
Estimate (SE) P-value

Villalta mean scores*†:
At 6 months
169 3.70 (0.51) 149 5.38 (0.50)
-1.68 (0.47)
<0.001
At 12 months
155 3.78 (0.50) 137 5.43 (0.49)
-1.65 (0.45)
<0.001
At 18 months
139 3.86 (0.52) 123 5.49 (0.50)
-1.62 (0.48)
<0.001
At 24 months
145 3.95 (0.54) 133 5.54 (0.54)
-1.60 (0.54)
0.0033
‡§
VCSS mean scores :
At 6 months
168 1.82 (0.32) 145 2.98 (0.32)
-1.16 (0.28)
<0.001
ǁ
ǁ
ǁ
ǁ
At 12 months
151
134
At 18 months
135 1.67 (0.35) 121 3.43 (0.35)
-1.76 (0.34)
<0.001
At 24 months
132 1.98 (0.35) 122 2.80 (0.35)
-0.82 (0.34)
0.018
‡ **
SF-36 general Quality of Life :
PCS: Change, baseline to 24 months
141 10.65 (0.95) 128 11.43 (0.99) -0.78 (1.17)
0.51
MCS: Change, baseline to 24 months
141 2.85 (0.82) 128 4.02 (0.86)
-1.17 (1.09)
0.28
‡ ††
VEINES disease-specific Quality of Life :
Overall: Change, baseline to 24 months
141 28.63 (1.97) 128 23.02 (2.07) 5.61 (2.6)
0.029
Symptoms: Change, baseline to 24 months 140 21.45 (1.96) 128 16.24 (2.06) 5.21 (2.56)
0.043
‡‡
§§
Leg pain severity (7-point scale):
Change, baseline to Day 10
181 -1.76 (0.14) 177 -1.25 (0.14) -0.51 (0.19)
0.0093
Change, baseline to Day 30
178 -2.36 (0.15) 171 -1.80 (0.15) -0.56 (0.21)
0.0082
‡‡
ǁǁ
Index leg circumference (cm):
Change, baseline to Day 10
175 -0.79 (0.23) 177 0.22 (0.23)
-1.00 (0.32)
0.0019
Change, baseline to Day 30
174 -1.37 (0.22) 170 -0.10 (0.23) -1.27 (0.32)
<0.001
* Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and piecewise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race)
†
Villalta scores (0-33 range) – higher is worse
‡
Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and piecewise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race, Villalta score)
§
VCSS scores (0-27 range) – higher is worse
ǁ Model estimates are unchanged from month 6 to month 12 due to the lack of a significant time trend
**
SF-36 major scales: physical component score (PCS, 0-100 range) and mental component score (MCS, 0-100
range) – higher is better, with a difference of 3 to 4 points considered clinically meaningful; †† VEINES overall
score (0-100 range) and symptom specific score (0-100 range) – higher is better; ‡‡ Mean change scores, SEs, and
treatment differences estimated using multiple linear regression adjusted for center; §§ patient-reported severity of
pain in the index leg (0-7 range) – higher is worse; ǁǁ leg circumference measured at 10cm below tibial tuberosity
of the index leg.
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Figure Legends

Figure 1. Patient flow diagram for the iliofemoral DVT subgroup in the ATTRACT trial.
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep-vein thrombosis; LEP,
Late Endovascular Procedure (not including inferior vena cava filter).

Figure 2. Subgroup analysis of PTS in patients with iliofemoral DVT.
Forest plot of risk ratios (PCDT versus No PCDT) for the occurrence of PTS from 6 to 24
months among subgroups of patients. The horizontal lines represent 99% confidence intervals.
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis.

Figure 3: LOESS* of raw and predicted mean Villalta scores by treatment group
Graphical display (locally weighted scatterplot smoothing) of the Villalta Scores evaluating PTS
severity by treatment arm, derived from piecewise-linear growth-curve models of the repeated
assessments from baseline through 24 months.

Figure 4. Subgroup analysis of moderate-or-severe PTS in patients with iliofemoral DVT.
Forest plot of risk ratios (PCDT versus No PCDT) for the occurrence of moderate-or-severe PTS
from 6 to 24 months among subgroups of patients. The horizontal lines represent 99%
confidence intervals.
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis.
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Patients with Iliofemoral DVT
n = 391

PCDT
n = 196

No PCDT
n = 195
n = 608

Did not get PCDT in first 7 days (n=6)
LEP done during 24 months (n=12)

Treatment

Received PCDT in first 7 days (n=4)
LEP done during 24 months (n=9)

Completed 24 months (n=145)

Completed 24 months (n=135)

Follow-up <24 months (n=51):

Follow-up <24 months (n=60):

- Death (n=5)
- Withdrew consent (n=9)
- Lost to follow-up (n=37)

Follow-up

- Death (n=6)
- Withdrew consent (n=16)
- Lost to follow-up (n=38)

1.1
Completed 4 assessments (n=120)
Completed 1-3 assessments (n=58)
Missed all 4 assessments (n=18)

n = 196 (modified ITT)
n = 190 (per-protocol)

PTS
Assessments
6-24 months

Analyzed

Completed 4 assessments (n=110)
Completed 1-3 assessments (n=54)
Missed all 4 assessments (n=31)

n = 195 (modified ITT)
n = 191 (per-protocol)

PTS defined as Villalta score ≥ 5 or ulcer
Risk Ratio (99% CI)

Baseline Factor

Subgroup

PCDT vs No PCDT

Age

< 65
≥ 65

71/157 vs 84/164
25/39 vs 16/31

0.15

Sex

Female
Male

42/89 vs 41/94
54/107 vs 59/101

0.28

Race

African American
White

15/33 vs 21/35
78/158 vs 74/148

0.43

Leg symptom
duration

< 1 week
≥ 1 week

59/128 vs 62/121
37/68 vs 38/74

0.43

Side of DVT

Left
Right

58/124 vs 65/125
38/72 vs 35/70

0.44

Major risk factor

Yes
No

14/29 vs 21/38
82/167 vs 79/157

0.67

Villalta
severity
score

0-4
5-9
10-14
≥ 15

7/24 vs 10/31
35/65 vs 28/65
27/60 vs 31/56
27/47 vs 31/42

0.22

Leg pain severity

1-2
3-4
5-7

15/34 vs 17/43
32/60 vs 28/59
48/99 vs 54/91

0.29

Between-Leg
circumference
difference

< 3 cm
≥ 3 cm

37/68 vs 33/71
58/122 vs 64/120

0.20

0.25

0.50

Favors PCDT

1.0

2.0

P Interaction

4.0

Favors No PCDT
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Moderate-or-severe PTS defined as Villalta score ≥ 10 or ulcer
Baseline Factor

Subgroup

PCDT vs No PCDT

Age

< 65
≥ 65

25/157 vs 49/164
11/39 vs 6/31

0.04

Sex

Female
Male

16/89 vs 23/94
20/107 vs 32/101

0.57

Race

African American
White
< 1 week
≥ 1 week

8/33 vs 12/35
27/158 vs 39/148
21/128 vs 35/121
15/68 vs 20/74

0.98

Side of DVT

Left
Right

22/124 vs 39/125
14/72 vs 16/70

0.32

Major risk factor

Yes
No

3/29 vs 15/38
33/167 vs 40/157

0.05

Villalta severity score

0-4
5-9
10-14
≥ 15

2/24 vs 2/31
11/65 vs 11/65
10/60 vs 19/56
13/47 vs 23/42

0.38

Leg pain severity

1-2
3-4
5-7

4/34 vs 5/43
13/60 vs 17/59
18/99 vs 33/91

0.44

Between-leg
circumference
difference

< 3 cm
≥ 3 cm

13/68 vs 21/71
22/122 vs 31/120

0.85

Leg symptom
duration

Risk Ratio (99% CI)

P Interaction

0.35

0.125

0.

Favors PCDT

1.0

2.0

8.0

Favors No PCDT

